Cover Image

EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

Show other versions (1)

EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German P...

Full description

Saved in:
Bibliographic Details
Main Authors: Penzel, Roland (Author) , Sers, Christine (Author) , Chen, Yuan (Author) , Lehmann-Mühlenhoff, Ulrich (Author) , Merkelbach-Bruse, Sabine (Author) , Jung, Andreas (Author) , Kirchner, Thomas (Author) , Büttner, Reinhard (Author) , Kreipe, Hans H. (Author) , Petersen, Iver (Author) , Dietel, Manfred (Author) , Schirmacher, Peter (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: Virchows Archiv
Year: 2011, Volume: 458, Issue: 1, Pages: 95-98
ISSN:0945-6317
Online Access: Get full text
Author Notes:hRoland Penzel, Christine Sers, Yuan Chen, Ulrich Lehmann-Mühlenhoff, Sabine Merkelbach-Bruse, Andreas Jung, Thomas Kirchner, Reinhard Büttner, Hans H. Kreipe, Iver Petersen, Manfred Dietel, Peter Schirmacher
Description
Summary:EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German Panel for Mutation Analyses in NSCLC demonstrates (a) a higher than previously reported mutation frequency outside the conventionally tested exons 19 and 21 and (b) an overall superiority of sequencing based assays over mutation-specific PCR. The implications for future diagnostic EGFR mutation testing are discussed.
ISSN:0945-6317

Similar Items